Seattle, WA -- (SBWIRE) -- 11/07/2019 -- Blood irradiators are used to in the treatment of graft-versus-host disease (GVHD) and in various medical and research applications such as preparing blood for transfusion and cancer research. These irradiators irradiate blood and blood components in order to prevent the proliferation of T lymphocytes that can inhibit the immune response, which otherwise may cause GVHD. Transfusion recipients at risk for GVHD such as fetuses receiving intrauterine transfusions, patients undergoing hematopoietic transplantation, and individuals receiving platelets are required to undergo irradiation procedure. Blood irradiation plays a major role in surgeries, cancer treatment, chronic illnesses, and traumatic injuries.
Blood irradiator aids in preventing from GVHD, a rare but serious complication of transfusion complication of blood transfusion. According to the Royal Children's Hospital Melbourne, transfusion-associated GVHD occurs when donor lymphocytes from transfused blood engraft in the recipient, thereby leading to hepatitis, diarrhea, and pancytopenia with clinical features of fever and skin rash. Moreover, the condition is fatal in over 90% of cases.
Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/1972
Major government and non-profit organizations are focused on offering financial aid for R&D of blood irradiators, which is expected to propel growth of the global blood irradiator market. For instance, in 2014, Stellarray, Inc., a developer of novel x-ray sources, was awarded the US$ 1.1 Mn grant by the Department of Energy to develop and commercialize new generation irradiators for ensuring the safety of blood transfusions by replacing cesium 137, which is identified as a national security hazard. Moreover, the Advancing Transfusion Cellular Therapies Worldwide (AABB) works in collaboration with the Food and Drug Administration (FDA) to ensure appropriate irradiation guidance and regulations for blood products, thereby favoring the blood irradiators market by maintaining security and compliance to limit the use of radioactive irradiators.
However, high cost of the irradiators and lack of awareness among population regarding uses and advantages of irradiators is expected to hamper growth of the market. For instance, according to the survey by College of American Pathologists, 2017, the cost of X-ray irradiators is around US$ 250,000 to US$ 300,000, with annual service contract accounting for US$ 15,000 to US$ 20,000.
The market in North America is expected to account for the largest market share over the forecast period. This is attributed to increasing product development. For instance, in September 2017, Typenex Medical, launched Rad-Control, a new irradiation indicator tag technology, in the blood banks and blood centers in the U.S. and Canada. Rad-control ensures that blood component has received irradiation, thereby preventing life threatening TA-GvHD.
Moreover, increasing adoption of X-ray irradiators is also expected to propel growth of the market. For instance, in 2017, the U.S. Department of Energy's National Nuclear Security Administration (DOE/NNSA) partnered with the New York City Department of Health and Mental Hygiene (DOHMH) and the Nuclear Threat Initiative (NTI) to replace the radioactive irradiators with the safer X-ray alternatives.
Increasing use of blood irradiators in medical settings to prevent and control the transmission of TA-GVHD is expected to boost growth of the market in North America. For instance, according to the Department of Health and Human Services, 2013, around 500 blood irradiators irradiated around 2 million blood units in 2013.
For more information, see Download PDF Copy Here @ https://www.coherentmarketinsights.com/insight/request-pdf/1972
Major players operating in the global blood irradiator market are focused on adopting collaboration strategies to enhance their market share. For instance, Charter Medical collaborated with RadTag Technologies to distribute the RadTag blood irradiator indicators in the U.S.
Key players operating in the global blood irradiator market include, Typenex Medical, Gamma-Service Medical GmbH, Rad Source Technologies, Sukosol Group, Cegelec NDT-PES, and Best Theratronics, Ltd.